AstraZeneca PLC on Friday reported positive results from planned interim analysis of a phase three trial evaluating its Imfinzi drug in gastric and gastroesophageal junction cancers.
The. | June 2, 2023
By Anthony O. Goriainoff AstraZeneca said Thursday that its and MSD s Lynparza cancer treatment had been approved in the U.S. for the treatment of metastatic castration-resistant prostate. | June 1, 2023
0947 GMT - AstraZeneca is among the most mentioned companies across news items over the past six hours, according to Factiva data. The Anglo-Swedish company said the U.S. drug regulator approved. | June 1, 2023
AstraZeneca PLC on Thursday hailed another approval for cancer drug Lynparza, while it ceased its development programme for Crohn s disease-focused brazikumab.
The Cambridge-based pharmaceutical. | June 1, 2023
By Anthony O. Goriainoff AstraZeneca said Thursday that it was discontinuing the brazikumab inflammatory bowel disease development program after reviewing its development timeline as well as. | June 1, 2023